Highlights from the newly released clinical guideline from the New York State Department of Health AIDS Institute for use of CAB/RPV LA as replacement antiretroviral therapy in virally-suppressed adults with HIV.
Switching HIV treatments from a daily pill to a monthly injectable has given Mike Hellman more freedom outdoors.
Patients given a 600 mg injection of cabotegravir still had detectable levels of the drug in plasma, tissues, and fluids for 12 weeks.
Despite HIV pre-exposure prophylaxis (PrEP) being available in France and reimbursed through the country’s social security system, the treatment remains underutilized among men who have sex with men.
This study offers reassurance that transgender women can safely and effectively use PrEP with hormone therapy.
Zambian study suggests men feel uncomfortable in women-dominated antenatal classes, resulting in many having unanswered questions about pregnancy and HIV.
ENYO Pharma announces 16 weeks vonafexor (EYP001) top-line interim results from two on-going Phase 2a studies in chronic hepatitis B patients.
Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19.
The study will evaluate the effects of an antiretroviral regimen change among people living with HIV who have experienced excessive weight gain when on a regimen that includes an integrase strand transfer inhibitor and tenofovir alafenamide/emtricitabine (TAF/FTC) or TAF/lamivudine (TAF/3TC).
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.